The original success of Sildenafil undeniably revolutionized the medication landscape, but placing funds in companies strongly reliant on generic versions presents a challenging picture. Although early returns were impressive, the end of patents and the appearance of cheaper alternatives have weakened sales. Consequently, a thorough evaluation of o